

I hereby certify that the foregoing correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 018623-008050US

PATENT

Assistant Commissioner for Patents
Washington, D.C. 20231

On October 1, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hardin



RECEIVED

OCT 12 1999

TECHNICAL 10/13/2000
#8B w/dsk
ID
20
99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/017,743

Filed: February 3, 1998

For: HLA BINDING PEPTIDES AND
THEIR USES

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed September 3, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 2, line 26, insert --(SEQ ID NOS:128 and 129)-- after "carboxy terminus".